Naderi Mohammad, Hashemi Mohammad, Soroush Navid, Amininia Shadi, Taheri Mohsen
Infectious Diseases and Tropical Medicine Research Center, Zahedan University of Medical Sciences, Zahedan, Iran.
Cellular and Molecular Research Center, Zahedan University of Medical Sciences, Zahedan, Iran. AND Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.
Acta Med Iran. 2016 May;54(5):308-12.
There are conflicting results concerning DC-SIGN and DC-SIGNR VNTR polymorphisms. The present study aimed to evaluate the possible association between DC-SIGN as well as DC-SIGNR VNTR polymorphisms and pulmonary tuberculosis (PTB) in a sample of Iranian population. This case-control study was done on 171 PTB and 161 healthy subjects. The variants were detected by polymerase chain reaction (PCR). DC-SIGNR VNTR genotypes in cases were 12.7% for 5/5, 2.4% for 6/5, 32.7% for 7/7, 38.2% for 7/5, 5.5% for 7/6, 1.2% for /5, 0.6% for 9/6, 6.7% for 9/7 in PTB patients and 19.7% for 5/5, 2.0% for 6/5, 31.6% for 7/7, 37.5% for 7/5, 5.7% for 7/6, 0.0% for 9/5, 0.7% for 9/6, 2.6% for 9/7 in controls. The findings showed no significant association between DC-SIGNR VNTR polymorphism and PTB. All subjects in cases and controls were 7/7 genotype regarding DC-SIGN VNTR polymorphism. Our data propose that DC-SIGNR VNTR, as well as DC-SIGN VNTR, were not associated with the risk of PTB in a sample of Iranian population.
关于DC-SIGN和DC-SIGNR可变数目串联重复序列（VNTR）多态性的研究结果存在冲突。本研究旨在评估伊朗人群样本中DC-SIGN以及DC-SIGNR VNTR多态性与肺结核（PTB）之间的可能关联。这项病例对照研究对171例PTB患者和161名健康受试者进行。通过聚合酶链反应（PCR）检测变异。PTB患者中DC-SIGNR VNTR基因型5/5为12.7%，6/5为2.4%，7/7为32.7%，7/5为38.2%，7/6为5.5%，9/5为1.2%，9/6为0.6%，9/7为6.7%；对照组中5/5为19.7%，6/5为2.0%，7/7为31.6%，7/5为37.5%，7/6为5.7%，9/5为0.0%，9/6为0.7%，9/7为2.6%。结果显示DC-SIGNR VNTR多态性与PTB之间无显著关联。病例组和对照组中所有受试者关于DC-SIGN VNTR多态性均为7/7基因型。我们的数据表明，在伊朗人群样本中，DC-SIGNR VNTR以及DC-SIGN VNTR与PTB风险无关。
Zotero 插件